343 related articles for article (PubMed ID: 19828525)
21. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
22. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
23. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
24. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
25. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
26. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
27. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
28. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
Wolff ME
J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
[TBL] [Abstract][Full Text] [Related]
29. Taking TRIPS to India--Novartis, patent law, and access to medicines.
Mueller JM
N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
[No Abstract] [Full Text] [Related]
30. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
31. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
32. Overview of the Hatch-Waxman Act and its impact on the drug development process.
Mossinghoff GJ
Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
[No Abstract] [Full Text] [Related]
33. Implementation of the biosimilar pathway: economic and policy issues.
Grabowski H; Long G; Mortimer R
Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
[No Abstract] [Full Text] [Related]
34. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
35. Maximizing exclusivity for drug products.
French H
Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
[No Abstract] [Full Text] [Related]
36. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
Burshtein S
Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
[No Abstract] [Full Text] [Related]
37. Maintaining patents protecting biologics or small-molecule drugs.
Marimuthu G; Kumari S; Kandasamy M; Raghunathan S; Saberwal G
Nat Biotechnol; 2012 Jan; 30(1):50-3. PubMed ID: 22231094
[No Abstract] [Full Text] [Related]
38. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
Dougherty MP
Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
[TBL] [Abstract][Full Text] [Related]
39. Teva v. Eisai: what's the real "controversy"?
Wang GL
Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
[TBL] [Abstract][Full Text] [Related]
40. How Patent Troll Legislation Can Increase Timely Access to Generic Drugs.
Treasure CL; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):729-30. PubMed ID: 27183456
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
